Table 2.
Primary and secondary outcomes of the included studies
| Variables | Study | |||||
|---|---|---|---|---|---|---|
| Parameter | side | Pennington et al. | Song et al. | Kong et al. (PLA) | Kong et al. (DAA) | |
| Acetabular cup positioning | ||||||
| Cup inclination* | Dominant | 46.4 ± 4.31 |
38.59 ± 6.84 (18–72.5) |
39.35 ± 5.26 (23–48) |
39.42 ± 7.19 | |
| Non-dominant | 43.5 ± 5.22 |
37.5 ± 6.76 (15.5–70) |
40.35 ± 5.77 (25–55) |
42.61 ± 7.32 | ||
| Cup anteversion* | Dominant | NR |
22.01 ± 6.35 (7.5–41.5) |
22.44 ± 8.67 (1–41) |
15.79 ± 6.99 | |
| Non-dominant |
25.28 ± 7.16 (6.5–45) |
24.77 ± 10.44 (0–55) |
16.91 ± 7.49 | |||
|
Located within safe zone (% of cups) according to Lewinnek et al.** |
Dominant | Inclination: | 100% | 88% | NR | NR |
| Anteversion | NR | 71% | ||||
| both | NR | 62% | 32.25% | 81.37% | ||
| Non-dominant | Inclination: | 100% | 87% | NR | NR | |
| Anteversion | NR | 52% | ||||
| both | NR | 46% | 27.41% | 73.53% | ||
| The mean difference between both sides* | Inclination | 3 degrees |
1.08 ± 9.46 (− 47–26) |
Difference > 5 degrees in 77% | NR | |
| Anteversion | NR |
3.27 ± 7.37 (− 17.5–24.5) |
||||
| LLD (mm)* | Dominant | 0.5 ± 5.34 | NR | NR | NR | |
| Non-dominant | 0.0 ± 5.67 | |||||
|
Center of Rotation Medialization* |
Dominant | 0.4 ± 2.04 | NR | NR | NR | |
| Non-dominant | 1.7 ± 4.54 | |||||
| Functional outcomes | ||||||
| Follow up period (months) | NR | NR | 3 months | 17.11 ± 2.58 | ||
| HHS* | Dominant | NR | NR |
83.63 ± 9.02 (71–95) |
94.33 ± 4 | |
| Non-dominant |
81.11 ± 9.3 (68–95) |
93.01 ± 3.94 | ||||
| Complications | ||||||
| Dislocation** | Dominant | NR | 16 (3.21%) | 0 (0.0%) | 1 (0.98%) | |
| Non-dominant | 35 (7.02%) | 2 (0.0%) | 0 (0.0%) | |||
| PJI** | Dominant | NR | 0 (0.0%) | NR | ||
| Non-dominant | 1 (1.6%) | |||||
| vascular injury** | Dominant | NR | 0 (0.0%) | |||
| Non-dominant | 2 (1.96%) | |||||
| periprosthetic fracture** | Dominant | 3 (2.94%) | ||||
| Non-dominant | 1 (0.98%) | |||||
| LFCN palsy** | Dominant | 9 (8.82%) | ||||
| Non-dominant | 12 (11.76%) | |||||
| HO** | Dominant | 2 (1.96%) | ||||
| Non- dominant | 0 (0.0%) | |||||
*Data presented as Mean ± SD (range). **Data presented as percentages. LLD: leg length difference, PJI: periprosthetic joint infection, LFCN: lateral femoral cutaneous nerve, HO: heterotopic ossification, NR: not reported, PLA: posterolateral approach, DAA: direct anterior approach